Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 67, Issue 3, 2012, Pages 321-327

  Howarth, P ^a   Malling, H J ^b   Molimard, M ^c   Devillier, P ^d  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b University of Copenhagen   (Denmark)

^c University Hospital   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

grass pollen rhinoconjunctivitis; seasonal allergic rhinoconjunctivitis; sublingual allergen immunotherapy; symptom severity

Indexed keywords

ORALAIR; PLACEBO; POLLEN ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; HAY FEVER; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; PLACEBO EFFECT; POLLEN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SYMPTOMATOLOGY;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; ALLERGENS; CHILD; CHILD, PRESCHOOL; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; MALE; MIDDLE AGED; POACEAE; POLLEN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, SEASONAL; SEASONS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857192921     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2011.02759.x     Document Type: Article

References (17)

1. Dahl R, Andersen PS, Chivato T, Valovirta E, de Monchy J,. National prevalence of respiratory allergic disorders. Respir Med 2004; 98: 398-403.
2. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A,. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007; 120: 381-387.
3. Camelo-Nunes I, Solé D,. Allergic rhinitis: indicators of quality of life. J Bras Pneumol 2010; 36: 124-133.
4. Hankin CS, Cox L, Bronstone A,. The health economics of allergen immunotherapy. Immunol Allergy Clin North Am 2011; 31: 325-341.
5. Van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW, Durham SR, et al., European Academy of Allergology and Clinical Immunology Position Paper: consensus statement on the treatment of allergic rhinitis. Allergy 2000; 55: 116-134.
6. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al., Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl 86): 8-160.
7. Committee for Medicinal Products for Human Use. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/EWP/18504/2006. London. European Medicines Agency. Pre-authorisation evaluation of medicines for human use. 20 November 2008.
8. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling H-J, et al., Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62: 317-324.
9. Didier A, Worm M, Horak F, Sussman G, de Beaumont O, Le Gall M, et al., Sustained 3-year efficacy of pre and coseasonal 5-grass sublingual immunotherapy tablets in grass-pollen allergic rhinoconjunctivitis. J Allergy Clin Immunol 2011; 128: 559-566.
10. Grouin JM, Vicaut E, Jean-Alphonse S, Demoly P, Wahn U, Didier A, et al., A new primary efficacy endpoint for specific immunotherapy clinical trial. Clin Exp Allergy 2011; 41: 1282-1288.
11. Didier A, Malling HJ, Worm M, Horak F, Jäger S, Montagut A, et al., Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120: 1338-1345.
12. Wahn U, Tabar A, de Beaumont O, Kuna P, Le Gall M, Halken S, et al., Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009; 123: 160-166.
13. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS,. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006; 117: 1021-1035.
14. Horak F, Jaeger S, Worm M, Melac M, Didier A,. Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment. Clin Exp Allergy 2009; 39: 394-400.
15. Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Devillier P, Montagut A, et al., Early onset of action of a 5-grass pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009; 124: 471-477.
16. Wilson AM, O'Byrne PM, Parameswaran K,. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004; 116: 338-344.
17. Benninger M, Farrar JR, Blaiss M, Chipps B, Ferguson B, Krouse J, et al., Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol 2010; 104: 13-29.